HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

tetrakis(diisopropylguanidino) zinc phthalocyanine

structure in first source

Also Known As:

Zn-DIGP

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Alzeer, Jawad: 1 article (08/2013)
2.	Luedtke, Nathan W: 1 article (08/2013)
3.	Moelling, Karin: 1 article (08/2013)
4.	Noreen, Faiza: 1 article (08/2013)
5.	Vummidi, Balayeshwanth R: 1 article (08/2013)

Related Diseases

1.	Phototoxic Dermatitis (Phototoxicity) 08/16/2013 - "Zn-DIGP exhibits good cellular uptake and low toxicity in the dark (EC50 > 80 μM) and is well tolerated upon its intravenous injection into mice at 8 mg/kg. Upon photoexcitation with red laser light (660 nm), Zn-DIGP exhibits a high quantum yield for singlet oxygen formation (Φ ≈ 0.51) that results in potent phototoxicity to cell cultures (EC50 ≈ 0.16 μM). "
2.	Neoplasms (Cancer) 08/16/2013 - "Zn-DIGP therefore inhibits cancer growth by both light-dependent and light-independent pathways. " 08/16/2013 - "Zn-DIGP is also capable of inhibiting the formation of tumor colonies in the lungs of C57BL/6 mice injected with B16F10 cells. " 08/16/2013 - "To the best of our knowledge, Zn-DIGP is the first PDT agent that can facilitate the photodynamic treatment of primary tumors while simultaneously inhibiting the formation of metastatic tumor colonies by a light-independent mode of action. "

Related Drugs and Biologics

1.	Singlet Oxygen
2.	1-phenyl-3,3-dimethyltriazene (PDT)

Related Therapies and Procedures

1.	Lasers (Laser)
2.	Intravenous Injections